SpringWorks Therapeutics Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

SpringWorks Therapeutics hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-10.4%

Rückkaufsrendite

Gesamte Aktionärsrendite	-10.4%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

Nov 15

SpringWorks Therapeutics Merits A Speculative Buy

Nov 04

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Aug 07

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

May 11

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

May 03

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

Apr 25

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

Apr 19

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Sep 20

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Jun 07

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Feb 22

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Nov 09

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

Dec 30

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Dec 14

SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

Sep 15

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von SWTX in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von SWTX gestiegen sind.

Dividendenrendite im Vergleich zum Markt

SpringWorks Therapeutics Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von SWTX im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (SWTX)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (SWTX) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von SWTX im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von SWTX im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von SWTX, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da SWTX keine Ausschüttungen gemeldet hat.

SpringWorks Therapeutics Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

No longer forecast to breakeven

Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

New minor risk - Profitability

SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology

SpringWorks Therapeutics Merits A Speculative Buy

SpringWorks Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

CEO & Director notifies of intention to sell stock

Consensus revenue estimates increase by 35%

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Forecast to breakeven in 2026

SpringWorks Therapeutics, Inc. Appoints Dr. Martin Mackay to Its Board of Directors

SpringWorks Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Springworks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with Nf1-Pn

Chief Operating Officer notifies of intention to sell stock

SpringWorks Therapeutics, Inc. Announces Data to Be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

Consensus revenue estimates increase by 54%, EPS downgraded

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

SpringWorks Therapeutics, Inc. to Report Q1, 2024 Results on May 02, 2024

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

SpringWorks Therapeutics, Inc., Annual General Meeting, May 16, 2024

Consensus revenue estimates increase by 21%, EPS downgraded

SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Consensus revenue estimates increase by 33%, EPS downgraded

Price target increased by 7.7% to US$67.53

SpringWorks Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Price target increased by 11% to US$61.86

SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer

Consensus revenue estimates decrease by 13%

SpringWorks Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.999982 million.

New minor risk - Shareholder dilution

SpringWorks Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Consensus revenue estimates decrease by 29%

Price target increased by 15% to US$54.83

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

New minor risk - Share price stability

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

Consensus revenue estimates decrease by 26%

SpringWorks Therapeutics, Inc. Announces Positive Topline Results from the Phase 2B ReNeu Trial of Mirdametinib in NF1-PN

Consensus revenue estimates decrease by 12%

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

SpringWorks Therapeutics, Inc. Appoints Tai-An Lin as Chief Scientific Officer

Consensus revenue estimates fall by 81%

Price target decreased by 9.8% to US$50.50

SpringWorks Therapeutics, Inc.(NasdaqGS:SWTX) dropped from Russell Small Cap Comp Value Index

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

SpringWorks Therapeutics, Inc. Announces PDUFA Date Extension for Nirogacestat NDA

Insufficient new directors

Consensus revenue estimates increase by 125%

Springworks Therapeutics, Inc. Announces Data from Two Collaboration-Sponsored Clinical Studies Evaluating Nirogacestat in Combination with B-Cell Maturation Agent in Patients with Relapsed or Refractory Multiple Myeloma

Consensus revenue estimates decrease by 85%

Price target decreased by 12% to US$57.00

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Springworks Therapeutics Completes Submission of New Drug Application to the Fda for Nirogacestat for the Treatment of Adults with Desmoid Tumors

Price target decreased to US$64.50

Price target decreased to US$69.80

Price target decreased to US$69.80

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Springworks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

SpringWorks Therapeutics, Inc. Announces Resignation of Michael Burgess as the Head of Research and Development

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022

SpringWorks Therapeutics, Inc. announced that it expects to receive $224.349775 million in funding from EcoR1 Capital, LLC, Boxer Capital LLC, The Invus Group, LLC, Deerfield Management Company, L.P. Series C, Perceptive Advisors LLC and other investor

SpringWorks drops 21% as Allogene drops lead asset in combination study

SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15

Sizing Up SpringWorks Therapeutics

SpringWorks Therapeutics, Inc. Announces Resignation of Stephen Squinto as Member of the Board

Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

Price target decreased to US$95.40

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

SpringWorks Therapeutics, Inc., Annual General Meeting, May 19, 2022

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Springworks Therapeutics Announces Clinical Collaboration with Abbvie to Evaluate Nirogacestat in Combination with Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma

Springworks Therapeutics, Inc. Announces Dosing of First Patient in Phase 1B/2 Trial Evaluating Nirogacestat in Combination with Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma